Methotrexate-associated biochemical alterations in a patient with chronic neurotoxicity

Journal of Medical Biochemistry

Volumn 28, Issue 1, 2009, Pages 11-15

  Vezmar, Sandra ^a,b   Bode, Udo ^a   Jaehde, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

5 methyltetrahydrofolate; CSF; Methotrexate; Neurotoxicity; S adenosylmethionine

Indexed keywords

METHOTREXATE;

ADULT; AMNESIA; ARTICLE; ATAXIA; BRAIN DAMAGE; BRAIN INFECTION; CASE REPORT; CHRONIC DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; CONFUSION; CONSCIOUSNESS LEVEL; DEPRESSION; DRUG MEGADOSE; FEMALE; HUMAN; IRRITABILITY; LEUKOENCEPHALOPATHY; LYMPHATIC LEUKEMIA; MOOD DISORDER; NEUROPATHIC PAIN; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALITY DISORDER; SIDE EFFECT; SKULL IRRADIATION; SPEECH DISORDER; TREMOR;

EID: 60249101435     PISSN: 14528258     EISSN: 14528266     Source Type: Journal    
DOI: 10.2478/v10011-008-0027-y     Document Type: Article

References (22)

1. Walker RW, Allen JC, Rosen G, Caparros B. Transient cerebral dysfunction secondary to high-dose methotre xate. J Clin Oncol 1986; 4: 1845-50.
2. García-Tena J, López-Andreu JA, Ferrís J, Menor F, Mulas F, Millet E, et al. Intrathecal chemotherapy-related myeloencephalopathy in a young child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1995; 12: 377-85.
3. Oka M, Terae S, Kobayashi R, Sawamura Y, Kudoh K, Tha KK, et al. MRI in methotrexate-related leukoencephalopathy: Disseminated necrotising leukoencep halopathy in comparison with mild leukoencephalopathy. Neuroradiology 2003; 45: 493-7.
4. Allen JC, Rosen G, Mehta BM, Horten B. Leukoencephalopathy following high-dose iv methotrexate chemo therapy with leucovorin rescue. Cancer Treat Rep 1980; 64: 1261-73.
5. Meadows AT, Evans AE. Effects of chemotherapy on the central nervous system. A study of parenteral methotrexate in long-term survivors of leukemia and lymphoma in childhood. Cancer 1976; 37: 1079-85.
6. Ochs J, Mulhern R, Fairclough D, Parvey L, Whitaker J, Chien L, et al. Comparison of neuropsychologic functioning and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial radiation or parenteral methotrexate: a prospective study. J Clin Oncol 1991; 9: 145-51.
7. Paakko E, Harila-Saari A, Vanionpaa L, Himanen S, Pyhtinen J, Lanning M. White matter changes on MRI du ring treatment in children with acute lymphoblastic leukemia: Correlation with neuropsychological findings. Med Pediatr Oncol 2000; 35: 456-61.
8. Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973; 289: 770-3.
9. Colamaria V, Caraballo R, Borgna-Pignatti C, Marradi P, Balter R, Mazza C, et al. Transient focal leukoencephalopathy following intraventricular methotrexate and cytarabine. A complication of the Ommaya reservoir: case report and review of the literature. Childs Nerv Syst 1990; 6: 231-5.
10. Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003; 49: 92-104.
11. Quinn CT, Griener JC, Bottiglieri T, Hyland K, Farrow A, Kamen BA. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol 1997; 15: 2800-6.
12. Quinn CT, Griener JC, Bottiglieri T, Arning E, Winick NJ. Effects of intraventricular methotrexate on folate, adenosine, and homocysteine metabolism in cerebro spinal fluid. J Pediatr Hematol Oncol 2004; 26: 386-8.
13. Hyland K, Smith I, Bottiglieri T, Perry J, Wendel U, Clayton PT, et al. Demyelination and decreased S-adenosylmethionine in 5,10- methylenetetrahydrofolate reductase deficiency. Neurology 1988; 38: 459-62.
14. Surtees R, Clelland J, Hann I. Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies. J Clin Oncol 1998; 16: 1505-11.
15. Kishi T, Tanaka Y, Ueda K. Evidence for hypomethylation in two children with acute lymphoblastic leukemia and leu koencephalopathy. Cancer 2000; 89: 925-31.
16. Belz S, Frickel C, Wolfrom C, Nau H, Henze G. High-performance liquid chromatographic determination of methotrexate, 7-hydroxymethotrexate, 5-methyltetrahydrofolic acid and folinic acid in serum and cerebrospinal fluid. J Chromatogr B 1994; 661: 109-18.
17. US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. 2001.
18. Wagner J, Hirth Y, Claverie N, Danzin C. A sensitive high-performance liquid chromatographic procedure with fluorometric detection for the analysis of decarboxylated S-adenosylmethionine and analogs in urine samples. Anal Biochem 1986; 154: 604-17.
19. Surtees R, Hyland K. Cerebrospinal fluid concentrations of S-adenosylmethionine, methionine, and 5-methyltetrahydrofolate in a reference population: cerebrospinal fluid S-adenosylmethionine declines with age in humans. Biochem Med Metab Biol 1990; 44: 192-9.
20. Reynolds EH, Gallagher BB, Mattson RH, Bowers M, Johnson AL. Relationship between serum and cerebrospinal fluid folate. Nature 1972; 240: 155-7.
21. Becker A, Vezmar S, Linnebank M, Pels H, Bode U, Schlegel U, et al. Marked elevation of homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate. Int J Clin Pharmacol Ther 2007; 45: 504-15.
22. Struys EA, Jansen EEW, De Meer K, Jakobs C. Determination of S-adenosylmethionine and S-adenosylhomocysteine in plasma and cerebrospinal fluid by stable-isotope dilution tandem mass spectrometry. Clin Chem 2002; 46: 1650-61.